INS and Insulin resistance: Rosiglitazone was selected not only because of its ability to improve insulin sensitivity, but also because of its potential to stimulate adipocyte differentiation [18] since the insulin resistance in HIV disease is associated with changes in body fat distribution including loss of adipose tissue from the peripheral subcutaneous regions [1, 19, 20].